Dyspnea Clinical Trial
— DyHPOfficial title:
Prevalence and Characterization of Persistent Dyspnea After an Hospitalization for a Respiratory Disease
The investigators aim to make an overview of persistent dyspnea at the end of an hospitalization for a respiratory disease using an actual tool, the Multidisciplinary Dyspnea Profile questionnaire.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age over 18 years old - Able to respond the questionnaire - Presenting at admission a dyspnea over 3/10 on numerical analogic scale - Admitted for a respiratory cause Exclusion Criteria: - cognitive impairment - aphasia - no french-speaking person |
Country | Name | City | State |
---|---|---|---|
France | ADOREPS | Paris |
Lead Sponsor | Collaborator |
---|---|
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of persistent dyspnea in the end of an hospitalization for a a respiratory disease | An average of one week, until the end of the hospitalization | ||
Secondary | Characterization of persistent dyspnea using MDP | An average of one week, until the end of the hospitalization | ||
Secondary | Outcome of patients with persistent dyspnea after hospitalization | 6 months mortality, incidence of rehospitalization | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04688905 -
Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
|
||
Completed |
NCT03679312 -
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD
|
Phase 1/Phase 2 | |
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Active, not recruiting |
NCT03604822 -
Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS
|
N/A | |
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
Completed |
NCT02538770 -
Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization
|
N/A | |
Completed |
NCT02248831 -
Evaluation of Cardiopulmonary Diseases by Ultrasound
|
N/A | |
Recruiting |
NCT01655199 -
Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
Active, not recruiting |
NCT01440764 -
Aerosol Inhalation Treatment for Dyspnea
|
Phase 1/Phase 2 | |
Completed |
NCT01577407 -
Non Opioid Treatment for Experimental Dyspnea
|
Phase 3 | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Recruiting |
NCT04327882 -
Point-of-care Ultrasound Interest in Dyspneic Emergency Department Patients: an Observational Bicentric Study
|
||
Completed |
NCT05029986 -
Preventing Dyspnea During Speech in Older Speakers
|
N/A | |
Not yet recruiting |
NCT04181359 -
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Completed |
NCT04305639 -
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
|
||
Completed |
NCT04370990 -
Automated Oxygen Administration -Rethinking Interventions Alleviating Dyspnea in Patients With COPD
|
N/A | |
Completed |
NCT04375917 -
Is Reduced Hypoxia Through a Robot Intervention, Associated With Sensory and Emotional Descriptions of Dyspnea, Anxiety, Depression, Symptom Burden and Anxiolytics
|
N/A |